Allianz SE Raises Holdings in Zoetis Inc. $ZTS

Allianz SE increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 30.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,923 shares of the company’s stock after acquiring an additional 684 shares during the quarter. Allianz SE’s holdings in Zoetis were worth $456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Savvy Advisors Inc. grew its holdings in Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after acquiring an additional 1,114 shares during the last quarter. Sound Income Strategies LLC raised its stake in shares of Zoetis by 54.3% during the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after acquiring an additional 152 shares during the last quarter. Canoe Financial LP boosted its holdings in shares of Zoetis by 859.0% during the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after purchasing an additional 11,975 shares during the period. Strs Ohio bought a new stake in shares of Zoetis in the first quarter worth about $22,891,000. Finally, Soros Capital Management LLC grew its stake in shares of Zoetis by 32.0% in the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock worth $2,872,000 after purchasing an additional 4,230 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.2%

NYSE:ZTS opened at $121.04 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm’s 50-day moving average price is $141.57 and its 200-day moving average price is $151.73. The company has a market capitalization of $53.34 billion, a PE ratio of 20.83, a P/E/G ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 1-year low of $117.26 and a 1-year high of $181.85.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 33.67%.

Analyst Ratings Changes

A number of research analysts have commented on the company. Stifel Nicolaus set a $140.00 price target on Zoetis in a research report on Tuesday, November 4th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. BTIG Research reduced their price objective on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $180.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.